Dyne Therapeutics, Inc.

Massachusetts Institute of Technology

Scott Hilderbrand

Romesh R Subramanian

Mohammed T Qatanani

Timothy Weeden

Cody A Desjardins

John Najim

Brendan Quinn

Stefano Zanotti

Kim Tang

Roger Y Tsien

Stephen J Lippard

Shawn Burdette

Sean Spring

Grant K Walkup

Peiyi Shen

Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes comprising an oligonucleotide (e.g., useful for targeting DMPK) covalently linked to an antibody (e.g., anti-TfR1 antibody).

Muscle targeting complexes and formulations for treating myotonic dystrophy

Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes (e.g., wherein each complex is of the exemplary formula shown below) comprising a phosphorodiamidate morpholino oligomer (e.g., useful for targeting DMD) covalently linked to an antibody (e.g., anti-TfR1 antibody). In some embodiments, the complexes are formulated with histidine (e.g., L-histidine) and sucrose at a specified pH (e.g., about 5.0 to 7.0). Also provided are uses of these formulations for treating a subject having a mutated DMD allele associated with Duchenne Muscular Dystrophy.

Muscle targeting complexes and formulations for treating dystrophinopathies

The present invention is directed, in part, to fluorescein-based ligands for detection of metal ions, and methods of making and using the same.

Fluorescein-based metal sensors, and methods of making and using the same

Growing community of inventors

Cambridge, MA, United States of America

Scott Hilderbrand